Quintrio
Home

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Maze Therapeutics, Inc. Common Stock

MAZE

Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.

Last trade $32.89
Day change -$1.01 (-2.98%)
Day range $32.20 – $33.80
Volume 312,250
Market cap $1.85B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.85B
Price / earnings
—
Price / book
4.33×
Price / sales
92.69×
EV / sales
86.94×
EV / EBITDA
-10.7×

Profitability

Earnings per share
-$2.77
Return on assets
-29.61%
Return on equity
-35.35%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0.09×
Current ratio
14.14×
Quick ratio
14.14×
Cash ratio
5.45×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$115.26M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for MAZE, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025
Revenue$0$0$20M$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0
Gross profit$0$0$20M$0$0$0$0
Selling, general and administrative$11.3M$13.1M$12.41M$10.49M$7.78M$8.37M$7.82M
Research and development$40.22M$34.94M$34.15M$27.57M$25.19M$28.11M$27.58M
Total operating expenses$51.52M$48.04M$46.55M$38.06M$32.97M$36.47M$35.4M
Operating income-$51.52M-$48.04M-$26.55M-$38.06M-$32.97M-$36.47M-$35.4M
Interest expense-$975K-$931K-$866K$0$0$0$0
Income before taxes-$47.97M-$44.73M-$24.21M-$34.57M-$30.09M-$33.68M-$32.79M
Income taxes$0$0$0$0$0$0$0
Net income-$47.97M-$44.73M-$24.21M-$34.57M-$30.09M-$33.68M-$32.79M
Net income attributable to common shareholders-$47.97M-$44.73M-$24.21M-$34.57M-$30.09M-$33.68M-$32.79M
EBITDA-$51.13M-$47.64M-$26.11M-$37.56M-$32.39M-$35.83M-$34.72M
Basic earnings per share-$0.79-$0.76-$0.45-$0.64-$0.66-$0.77-$1.15
Diluted earnings per share-$0.79-$0.76-$0.45-$0.64-$0.66-$0.77-$1.15

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Wall Street Analysts Predict a 93.92% Upside in Maze Therapeutics, Inc. (MAZE): Here's What You Should Know

Maze Therapeutics (MAZE) has gained 22% over the past four weeks and closed at $32.25. Wall Street analysts have set a mean price target of $62.54, indicating a potential 93.9% upside. The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions. However, the article cautions that price targets alone should not be the sole basis for investment decisions, as analysts often set overly optimistic targets.

GlobeNewswire Inc.

Maze Therapeutics to Participate in Upcoming Investor Conferences

Maze Therapeutics announced that CEO Jason Coloma will participate in three investor conferences in November and December 2026, including the Guggenheim Healthcare Innovation Conference, Jefferies Global Healthcare Conference, and Evercore Healthcare Conference. Live webcasts will be available on the company's website.

Zacks Investment Research

What Makes Maze Therapeutics, Inc. (MAZE) a New Buy Stock

Maze Therapeutics, Inc. (MAZE) has been upgraded to a Zacks Rank #2 (Buy) rating, primarily driven by upward trends in earnings estimates. The company's Zacks Consensus Estimate has increased 1.2% over the past three months. The upgrade positions MAZE in the top 20% of Zacks-covered stocks, suggesting potential for near-term stock price appreciation based on improving earnings outlook.

Zacks Investment Research

How Much Upside is Left in Maze Therapeutics, Inc. (MAZE)? Wall Street Analysts Think 123.39%

Maze Therapeutics (MAZE) stock has gained 22.3% over the past four weeks and closed at $27.53. Wall Street analysts project a mean price target of $61.50, indicating potential upside of 123.4%. The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions, though the article cautions that price targets alone should not be the sole basis for investment decisions.

The Motley Fool

Maze Therapeutics CSBO Sells 7,500 Shares for $190,000 After Strong Trial Results and Q4 Financials

Atul Dandekar, Chief Strategy and Business Officer of Maze Therapeutics, exercised and sold 7,500 shares for approximately $190,000 on April 29, 2026, reducing his direct holdings by 41.66%. The sale was part of a Rule 10b5-1 trading plan and should not be interpreted as a signal about his conviction in the company. Maze reported positive phase 2 trial data for MZE829 in March and maintains $360 million in cash with runway into 2028.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.